Key result
P2Y12 receptor inhibitor plus aspirin given within 24 hours of acute noncardioembolic ischemic stroke or TIA reduced the risk of recurrent stroke compared to aspirin alone.
Why the study?
Antiplatelet therapy is central to managing acute ischemic stroke or TIA, but the efficacy and safety of a P2Y12 receptor inhibitor plus aspirin versus aspirin alone initiated within 24 hours required assessment.
Does P2Y12 receptor inhibitor plus aspirin reduce recurrent stroke in patients with acute noncardioembolic ischemic stroke or TIA treated within 24 hours compared to aspirin alone?
Meta-Analysis (n=21,808)
Does P2Y12 receptor inhibitor plus aspirin reduce recurrent stroke in patients with acute noncardioembolic ischemic stroke or TIA treated within 24 hours compared to aspirin alone?
Dual antiplatelet therapy with a P2Y12 inhibitor and aspirin within 24 hours of acute noncardioembolic ischemic stroke or TIA reduces recurrent stroke, though ticagrelor increases severe bleeding risk compared to clopidogrel.
Answers are grounded in this paper and cite their sources.
Supports early dual antiplatelet therapy in acute noncardioembolic stroke or TIA; confirms recurrent stroke reduction across randomized trials.
BACKGROUND/PURPOSE: Antiplatelet therapy is the cornerstone for acute ischemic stroke or transient ischemic attack (TIA). The purpose of this study was to conduct a meta-analysis to assess the efficacy and safety of P2Y12 receptor inhibitor plus aspirin versus aspirin alone treated within 24 h after acute noncardioembolic ischemic stroke or TIA. METHODS: We search Pubmed, EMBASE, CENTRAL and clinicaltrials.gov from January 1966 to January 2021. We included randomized trials which compared P2Y12 receptor inhibitor plus aspirin versus aspirin alone. Relative risk (RR) with 95% confidence (CI) was used as a measure of P2Y12 receptor inhibitor plus aspirin versus aspirin. The primary efficacy endpoint was recurrent stroke and the primary safety endpoint was severe bleeding. RESULTS: The search identified 5 randomized trials comparing P2Y12 receptor inhibitor plus aspirin and aspirin with 21,808 individuals enrolled. Pooled results from these trials showed that P2Y12 receptor inhibitor plus aspirin compared with aspirin was associated with a lower risk of recurrent stroke (RR 0.75, 95% CI 0.68 to 0.83). Ticagrelor plus aspirin compared with aspirin was associated with increased risk of severe bleeding (RR 3.98, 95% CI 1.74 to 9.10) and intracranial hemorrhage (RR 3.32, 95% CI 1.33 to 8.25), whereas clopidogrel plus aspirin vs. aspirin had similar hemorrhagic risk. CONCLUSION: P2Y12 receptor inhibitor plus aspirin vs aspirin given within 24 h after acute noncardioembolic ischemic stroke or TIA reduces the risk of subsequent stroke. However, the risk of severe bleeding, including intracranial hemorrhage, was higher with ticagrelor plus aspirin vs aspirin. PROSPERO ID: CRD42020203730.
No takes yet. Share an insight, caveat, or question.
Huang et al. (2021) conducted a meta-analysis in acute noncardioembolic ischemic stroke or TIA (n=21,808). P2Y12 receptor inhibitor plus aspirin vs. aspirin alone was evaluated on recurrent stroke (RR 0.75, 95% CI 0.68 to 0.83). P2Y12 receptor inhibitor plus aspirin given within 24 hours of acute noncardioembolic ischemic stroke or TIA reduced the risk of recurrent stroke compared to aspirin alone.
Synapse has enriched 10 related papers. Consider them for comparative context: